Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Lindner

Showing results (661-670 of 708) with videos related to

Pageof 71
Sort By:
Journal of Cancer Research and Clinical Oncology|April 26, 2025
First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysisAnton Burkhard-Meier, Vera Valerie Rechenauer, Vindi Jurinovic, et al.
Circulation|August 4, 2011
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsiaRavi Thadhani, Tuelay Kisner, Henning Hagmann, et al.
Acta Oncologica (Stockholm, Sweden)|January 15, 2025
Maintenance treatment with trofosfamide in patients with advanced soft tissue sarcoma - a retrospective single-centre analysisAnton Burkhard-Meier, Vera Valerie Rechenauer, Luc M Berclaz, et al.
JAMA Oncology|May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-upHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Nature Communications|June 14, 2019
Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin systemLaura Rinaldi, Rossella Delle Donne, Bruno Catalanotti, et al.
JAMA Oncology|December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical TrialHans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.
The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 8, 2022
Hyperthermia-induced doxorubicin delivery from thermosensitive liposomes via MR-HIFU in a pig modelLukas Christian Sebeke, Juan Daniel Castillo Gómez, Edwin Heijman, et al.
FEBS Letters|August 20, 2019
LAMTOR/Ragulator regulates lipid metabolism in macrophages and foam cell differentiationGiorgia Lamberti, Cedric H De Smet, Mihaela Angelova, et al.
Nature Communications|May 29, 2024
Author Correction: Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin systemLaura Rinaldi, Rossella Delle Donne, Bruno Catalanotti, et al.
Pageof 71

Showing results (661-670 of 708) with videos related to

Sort By:
Pageof 71
Journal of Cancer Research and Clinical Oncology|April 26, 2025
First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysisAnton Burkhard-Meier, Vera Valerie Rechenauer, Vindi Jurinovic, et al.
Circulation|August 4, 2011
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsiaRavi Thadhani, Tuelay Kisner, Henning Hagmann, et al.
Acta Oncologica (Stockholm, Sweden)|January 15, 2025
Maintenance treatment with trofosfamide in patients with advanced soft tissue sarcoma - a retrospective single-centre analysisAnton Burkhard-Meier, Vera Valerie Rechenauer, Luc M Berclaz, et al.
JAMA Oncology|May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-upHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Nature Communications|June 14, 2019
Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin systemLaura Rinaldi, Rossella Delle Donne, Bruno Catalanotti, et al.
JAMA Oncology|December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical TrialHans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.
The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 8, 2022
Hyperthermia-induced doxorubicin delivery from thermosensitive liposomes via MR-HIFU in a pig modelLukas Christian Sebeke, Juan Daniel Castillo Gómez, Edwin Heijman, et al.
FEBS Letters|August 20, 2019
LAMTOR/Ragulator regulates lipid metabolism in macrophages and foam cell differentiationGiorgia Lamberti, Cedric H De Smet, Mihaela Angelova, et al.
Nature Communications|May 29, 2024
Author Correction: Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin systemLaura Rinaldi, Rossella Delle Donne, Bruno Catalanotti, et al.
Pageof 71